Report: CRO participation in clinical trial design projected to increase 206% by 2020
Pharmaceutical and medical device teams plan to increasingly involve CROs in their clinical trial planning processes. The largest projected change is the level of vendor involvement in trial design activities, according to a recent report issued by pharmaceutical intelligence provider Cutting Edge Information.
Surveyed companies report that they currently share strategic planning duties with vendors at 17% of organizations. By 2020, the number of teams planning to share these trial design responsibilities with CROs is expected to increase to 52%.
"Projected changes to sponsor-CRO working relationships owe largely to shifts within large and mid-sized pharma companies," said Sarah Ray, senior analyst at Cutting Edge Information. "In 2014, no surveyed Top 10 or Top 50 team reported sharing trial design responsibilities with CROs or other third parties. This is drastically changing, however, as half of these surveyed teams plan to involve vendors in the clinical trial design process within the next three to five years."
Changes to other surveyed team types are more varied. Like surveyed large pharmaceutical organizations, device teams also report plans to increase vendor involvement in their clinical trial design activities. In 2014, all surveyed device teams retained trial planning responsibilities exclusively in-house. However, an estimated quarter of surveyed device teams plan to share trial design duties with CROs in the future.